Aditxt (ADTX) Income from Continuing Operations (2019 - 2026)
Aditxt (ADTX) recorded quarterly Income from Continuing Operations of 16189200.0 in Q1 2026, down 209.47% quarter-over-quarter from 5231251.0 in Q4 2025, and down 171.97% on a YoY basis from 22492897.59 in Q1 2025.
Aditxt (ADTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Aditxt's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 16189200.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 171.97% year-over-year to 16189200.0; the TTM figure through Mar 2026 stood at 53023778.0 (down 103.13% YoY), while the FY2025 annual figure was 42787043.0, down 22.18% from the prior year.
- Income from Continuing Operations was 16189200.0 for Q1 2026 at Aditxt, down from 5231251.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5231251.0 in Q4 2025 to a low of 24207669.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 9060977.88 across 5 years, with a median of 7395658.0 in 2025.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations surged 65.98% in 2022, then slumped 246.8% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 8183166.0 in 2022, then sank by 34.15% to 10977821.0 in 2023, then surged by 49.47% to 5547172.0 in 2024, then grew by 5.7% to 5231251.0 in 2025, then slumped by 209.47% to 16189200.0 in 2026.
- The last three Income from Continuing Operations figures came in at 16189200.0 (Q1 2026), 5231251.0 (Q4 2025), and 24207669.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Aditxt | 2,485.68 | -2.16 Mn | 2,868.00 | -16.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.19 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -24.21 Mn |
| Jun 30, 2025 | -7.40 Mn |
| Mar 31, 2025 | -5.95 Mn |
| Dec 31, 2024 | -5.55 Mn |
| Sep 30, 2024 | -6.98 Mn |
| Jun 30, 2024 | -7.62 Mn |
| Mar 31, 2024 | -14.87 Mn |
| Dec 31, 2023 | -10.98 Mn |
| Sep 30, 2023 | -9.75 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -5.98 Mn |
| Dec 31, 2022 | -8.18 Mn |
| Sep 30, 2022 | -7.56 Mn |
| Jun 30, 2022 | -5.85 Mn |
| Mar 31, 2022 | -6.06 Mn |
| Dec 31, 2021 | -24.05 Mn |
| Sep 30, 2021 | -9.76 Mn |
| Jun 30, 2021 | -6.18 Mn |